PMID- 28704214
OWN - NLM
STAT- MEDLINE
DCOM- 20190416
LR  - 20210816
IS  - 1473-5709 (Electronic)
IS  - 0959-8278 (Linking)
VI  - 27
IP  - 6
DP  - 2018 Nov
TI  - Bile acids upregulate BRCA1 and downregulate estrogen receptor 1 gene expression 
      in ovarian cancer cells.
PG  - 553-556
LID - 10.1097/CEJ.0000000000000398 [doi]
AB  - Two major risk factors for ovarian cancer include loss-of-function mutations in 
      the BRCA1 (breast cancer 1, early onset) gene and aspects of estrogen metabolism. 
      Modulation of the levels of the normal BRCA1 allele and estrogen receptor 
      expression may therefore be a preventive strategy. Consensus binding motifs for 
      the bile acid-responsive transcription factor farnesoid X receptor were 
      identified in the BRCA1 and estrogen receptor 1 (ESR1) and estrogen receptor 2 
      (ESR2) genes, supported by chromatin immunoprecipitation sequencing data. Two 
      major bile acids, deoxycholic acid (DCA) and chenodeoxycholic acid (CDCA), 
      resulted in a greater than four-fold induction of BRCA1 transcript levels at 
      10 mumol/l and a greater than six-fold induction at 50 mumol/l relative to 
      untreated control OVCAR3 ovarian cancer cells. Conversely, CDCA and DCA at 
      10 mumol/l resulted in about a 75% decrease in ESR1 expression in response to 
      10 mumol/l CDCA and DCA and close to 90% reduction with 50 mumol/l CDCA and DCA. 
      Bile acids had no effects on ESR2 gene transcript levels. The inverse regulation 
      of BRCA1 and ESR1 gene expression in response to physiological levels of bile 
      acids could have important implications for disease penetrance and 
      chemoprevention strategies in carriers of BRCA1 mutations.
FAU - Jin, Qunyan
AU  - Jin Q
AD  - Department of Medical Genetics and Molecular Biochemistry, Temple University 
      School of Medicine, Philadelphia, Pennsylvania, USA.
FAU - Noel, Olivier
AU  - Noel O
FAU - Nguyen, Mai
AU  - Nguyen M
FAU - Sam, Lionel
AU  - Sam L
FAU - Gerhard, Glenn S
AU  - Gerhard GS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Cancer Prev
JT  - European journal of cancer prevention : the official journal of the European 
      Cancer Prevention Organisation (ECP)
JID - 9300837
RN  - 0 (BRCA1 Protein)
RN  - 0 (BRCA1 protein, human)
RN  - 0 (Bile Acids and Salts)
RN  - 0 (ESR1 protein, human)
RN  - 0 (ESR2 protein, human)
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (Receptors, Cytoplasmic and Nuclear)
RN  - 0C5V0MRU6P (farnesoid X-activated receptor)
SB  - IM
MH  - BRCA1 Protein/genetics/*metabolism
MH  - Bile Acids and Salts/*metabolism
MH  - Cell Line, Tumor
MH  - Down-Regulation
MH  - Estrogen Receptor alpha/genetics/*metabolism
MH  - Estrogen Receptor beta/genetics/metabolism
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Loss of Function Mutation
MH  - Ovarian Neoplasms/genetics/*pathology
MH  - Receptors, Cytoplasmic and Nuclear/metabolism
MH  - Up-Regulation
EDAT- 2017/07/14 06:00
MHDA- 2019/04/17 06:00
CRDT- 2017/07/14 06:00
PHST- 2017/07/14 06:00 [pubmed]
PHST- 2019/04/17 06:00 [medline]
PHST- 2017/07/14 06:00 [entrez]
AID - 10.1097/CEJ.0000000000000398 [doi]
PST - ppublish
SO  - Eur J Cancer Prev. 2018 Nov;27(6):553-556. doi: 10.1097/CEJ.0000000000000398.